EUCTR2007-001754-11-IT进行中（未招募）不适用
Pilot study to evaluate the effect of Rituximab in combination with MTX in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by magnetic resonance imaging (MRI) in the hand of patients with rheumatoid arthritis. - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients capable of understanding and signing the informed consent and of respecting the procedures involved in the study
- •2. Patients with rheumatoid arthritis diagnosed for at least 3 months according to the 1987 criteria of the American College of Rheumatology (ACR)
- •3. Patients experiencing inadequate response to MTX at a dose of 12.5 25 mg/week (p.o. or parenteral) for at least 12 weeks, with the last 4 weeks prior to baseline maintained at a stable dose. A MTX dose of 7.5 or 10 mg/week is permitted only in case of documented intolerance to higher doses .
- •4. Disease duration <= 10 years
- •5. Anti-CCP and / or RF positive
- •6. Patients with a DAS 28-CRP > 3.2
- •7. At screening: C reactive protein (CRP) > 0.6 mg/dL (6 mg/L) or ESR > 28 mm/h.
- •8. Age: 18-75 years.
- •9. Evidence of erosive disease and/or clinical synovitis in a signal (MRI) joint (metacarpophalangeal and/or wrist)
- •10. RA duration > 1 year: at least one erosion evaluated by a radiograph at the X-ray and evidence of clinical synovitis
- •11. RA duration < 1 year: evidence of clinical synovitis
- •12. The use of glucocorticoids (< 10 mg/day prednisolone or equivalent) is allowed, providing they have been taken at a stable dosage for at least 4 weeks before baseline.
- •13. The use of NSAIDs is allowed providing they have been taken at a stable dosage for at least 4 weeks before baseline.
- •14. Potentially fertile women may participate in the study only if during the course of the study and for at least a year after treatment, they do not become pregnant.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria related to rheumatoid arthritis
- •1. Autoimmune rheumatic diseases other than RA. A past or present medical record reporting inflammatory joint diseases other than RA (e.g. gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or any other systemic autoimmune disease (e.g. SLE, inflammatory intestinal disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or any other concomitant syndrome).General exclusion criteria
- •2. Surgical operations (including synovectomy) on bones/joints (including fusion or joint replacements) in the 12 weeks prior to the baseline visit or, in the case of scheduled surgery, within 48 weeks of randomization.
- •3. Absence of peripheral venous access.
- •4. Women who are pregnant or breast-feeding.
- •5. Significant heart disease (NYHA class III - IV) or lung disease, the latter unrelated to the pathology (including obstructive lung disease).
- •6. Evidence of a serious concomitant and uncontrolled disease concerning the nervous system, kidney, liver, endocrine glands or gastrointestinal tract, which, in the doctor's opinion, would preclude the participation of the patient.
- •7. Primary or secondary immunodeficiency (previous or currently active), including a history of HIV infection.
- •8. Active infections of any kind (excluding mycotic infections of the nail bed), or any important episode requiring hospitalisation or intravenous therapy with anti-infective agents in the 4 weeks prior to baseline or oral anti-infective agents in the 2 weeks prior to baseline.
- •9. A history of deep tissue infections (e.g. fasciitis, abscesses, osteomyelitis) within 52 weeks of selection.
- •10. A history of serious recurrent or chronic infections (to verify the presence of chest infections a chest x-ray will be performed at screening, if not already performed in the 12 weeks prior to screening).
- •11. Uncontrolled high or low blood pressure.
- •12. A history of neoplasia, including solid tumours, haematological neoplasia and carcinoma in situ in the previous 10 years (except for basal cell and squamous cell skin cancer already removed and healed).
- •13. Neurological disorders (congenital or acquired), vascular or systemic diseases that could interfere with the evaluation of efficacy, particularly with joint pain and swelling (e.g. Parkinson's disease, cerebral palsy, diabetic neuropathy).
- •14. Alcohol or drug abuse or a history of alcoholism or drugaddiction in the 24 weeks prior to baseline.
- •Exclusion criteria related to MRI
- •15. Impossibility to perform MRI due to known allergy to Gadoteridol or presence of metallic implants in the area to be examined.
- •Exclusion criteria related to therapy
- •16. Confirmed hypersensitivity to any component of Rituximab or to murine proteins.
- •17. Concomitant treatment with biological agents.
- •18. Previous treatment with more than one biological agent approved for RA.
- •19. Previous treatment with cell-depleting therapies, including experimental agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, anti-CD11a, anti-CD22, anti-BLys/ BAFF, and anti-CD20).
- •20. Previous treatment with any experimental agent within 28 days of baseline or within a period equal to five times the half-life of the experimental drug (whichever time is longest).
- •21. Administration of any vaccine within 28 days prior to baseline (it is recommended that a patient's vaccination record and the need for immunization prior to receiving
研究者
相似试验
进行中（未招募）
1 期
A multi-centre pilot study of Rituximab in patients with active PsAPsoriatic ArthritisEUCTR2006-000844-17-SKVienna Medical University30
未知
2 期
Clinical study for effectiveness of rituximab for acquired coagulopathyacquired coagulopathyJPRN-UMIN000024612Gunma University10
进行中（未招募）
不适用
A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens. The key role of IgG antibodies formation in the pathogenesis of IMN suggests that B cell depletion may favourably impact the evolution of the glomerular disease and reduce proteinuria. We propose this study in order to test in a randomized controlled trial the hypMedDRA version: 14.1Level: PTClassification code 10018372Term: Glomerulonephritis membranousSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-006115-59-ITAZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
已完成
不适用
ncontrolled trial of Rituximab treatment on refractory or steroid dependent nephrotic syndrome in adult.refractory or steroid dependent nephrotic syndromeJPRN-UMIN000014355Saitama Medical University Department of Nephrology5
进行中（未招募）
不适用
A randomized trial of Rituximab in induction therapy for living donor renal transplantation - Randomized trial of rituximab in renal transplantatioEnd stage renal diseaserenal function after renal transplantationMedDRA version: 17.0Level: PTClassification code 10038533Term: Renal transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2009-017066-23-GBGuys and St Thomas Foundation Trust